Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 StudyLisa Licitra, Robert I. Haddad, John Paul Shen et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 32